全文获取类型
收费全文 | 104008篇 |
免费 | 7089篇 |
国内免费 | 3392篇 |
专业分类
耳鼻咽喉 | 485篇 |
儿科学 | 1210篇 |
妇产科学 | 1522篇 |
基础医学 | 16901篇 |
口腔科学 | 1518篇 |
临床医学 | 6994篇 |
内科学 | 15317篇 |
皮肤病学 | 1627篇 |
神经病学 | 10632篇 |
特种医学 | 1539篇 |
外国民族医学 | 296篇 |
外科学 | 7120篇 |
综合类 | 14915篇 |
现状与发展 | 12篇 |
预防医学 | 4612篇 |
眼科学 | 815篇 |
药学 | 16217篇 |
7篇 | |
中国医学 | 3318篇 |
肿瘤学 | 9432篇 |
出版年
2024年 | 52篇 |
2023年 | 999篇 |
2022年 | 1352篇 |
2021年 | 2495篇 |
2020年 | 2280篇 |
2019年 | 2314篇 |
2018年 | 2525篇 |
2017年 | 2413篇 |
2016年 | 2530篇 |
2015年 | 2928篇 |
2014年 | 8387篇 |
2013年 | 8535篇 |
2012年 | 6600篇 |
2011年 | 7102篇 |
2010年 | 7594篇 |
2009年 | 7379篇 |
2008年 | 5967篇 |
2007年 | 4807篇 |
2006年 | 4179篇 |
2005年 | 3702篇 |
2004年 | 3422篇 |
2003年 | 3097篇 |
2002年 | 2674篇 |
2001年 | 2341篇 |
2000年 | 2077篇 |
1999年 | 1786篇 |
1998年 | 1764篇 |
1997年 | 1678篇 |
1996年 | 1426篇 |
1995年 | 1305篇 |
1994年 | 1265篇 |
1993年 | 1124篇 |
1992年 | 850篇 |
1991年 | 770篇 |
1990年 | 666篇 |
1989年 | 510篇 |
1988年 | 457篇 |
1987年 | 387篇 |
1986年 | 393篇 |
1985年 | 515篇 |
1984年 | 405篇 |
1983年 | 258篇 |
1982年 | 313篇 |
1981年 | 260篇 |
1980年 | 186篇 |
1979年 | 127篇 |
1978年 | 90篇 |
1977年 | 67篇 |
1976年 | 55篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Journal of microbiology, immunology, and infection》2022,55(2):273-281
BackgroundStenotrophomonas maltophilia, a species of highly genetic diversity, has emerged as an important nosocomial pathogen. S. maltophilia and Pseudomonas aeruginosa are often co-isolated from pneumonia patients. In our previous study, we have demonstrated that the pacIRA cluster present in some but not all clinical S. maltophilia isolates. Proteins encoded by pacIRA operon are an extracytoplasmic function (ECF) sigma factor, a transmembrane anti-sigma regulator, and a TonB-dependent receptor. This study aimed to elucidate PacIRA system function and its significance to S. maltophilia.MethodsThe pacI, pacR, and pacA genes were individually or totally deleted from the chromosome of KJΔEnt, a pacIRA-positive and siderophore-null strain. Growth promotion assay was performed to examine the implication of pacIRA system in iron utilization. Gene expression was quantified by quantitative real time PCR (qRT-PCR). Growth competition assay was executed to investigate the significance of pacIRA operon to S. maltophilia.ResultsPacIRA system contributed to utilize ferri-pyochelin of P. aeruginosa as iron sources for growth in an iron-depleted condition, but hardly utilized ferric citrate, hemin, ferri-stenobactin, and ferri-pyoverdine. PacIRA was founded to belong to Fur regulon and upregulated in response to iron-depleted stress. Growth competition assay demonstrated that pacIRA-positive S. maltophilia had a superiority over pacIRA-negative S. maltophilia in iron acquisition when they were co-cultured in P. aeruginosa ferri-pyochelin-supplemented medium.ConclusionsPacIRA system of S. maltophilia is a xenosiderophore uptake implement, involving in the acquisition of pyochelin of P. aeruginosa. 相似文献
3.
4.
5.
《Transfusion Clinique et Biologique》2022,29(3):269-272
A delayed haemolytic transfusion reaction (DHTR) encompasses a positive direct antiglobulin test (DAT) developed anytime between 24 hours to 28 days after cessation of transfusion, a positive eluate or a newly identified alloantibody in the plasma or serum along with features of haemolysis in the patient. Routinely, it is expected that with the transfusion of one unit of packed red cells in a patient of average height and weight, the haemoglobin level and hematocrit increase by 1 g/dL and 3% respectively. However, in a patient with DHTR, an inadequate rise of post-transfusion haemoglobin (< 1 g/dL) or rapid fall in haemoglobin back to pre-transfusion levels is observed. Kidd antibodies are particularly known to cause DHTR, maybe alone or in unison with other antibodies. Detection of these alloantibodies is consequential in providing good transfusion support to these patients. These events may be difficult to detect as they may present as varied clinical features or immunological nuisances. In this case series, we have presented three cases of DHTR with special emphasis on their clinical presentations, immunohaematological evaluations, laboratory parameters and the role of proper transfusion support in these patients to avoid further complications. 相似文献
6.
目的 分析术前SCC、CYFRA21-1与肺鳞癌临床病理特征、预后之间的关系。方法 收集2017年3月~2018年4月在云南省肿瘤医院确诊的肺鳞癌患者100例为观察组,确诊为肺良性肿瘤患者90名为肺良性肿瘤组、以及正常人群90名为健康人群组。通过电化学发光法对SCC、CYFRA21-1两种指标进行检测。检测SCC、CYFRA21-1含量,分析在肺鳞癌中表达的临床意义。结果 SCC、CYFRA21-1在肺鳞癌中比在肺良性肿瘤、健康人群中含量要高,差异有统计学意义(P<0.001),并且敏感性均高于其他两组;男性患者的SCC、CYFRA21-1含量高于女性患者,差异具有统计学意义(P<0.05);SCC、CYFRA21-1含量在年龄≥60岁的含量高于<60岁患者,差异无统计学意义(P>0.05);有吸烟史患者的SCC含量高于无吸烟史患者,差异无统计学意义(P>0.05)。CYFRA21-1在吸烟史患者中高表达,差异有统计学意义(P<0.05);SCC、CYFRA21-1在有淋巴结转移、远处转移、肿瘤直径≥5 cm、病理分期为晚期时高表达,差异具有统计学意义(P<0.05);SCC、CYFRA21-1阳性患者OS、PFS比阴性患者短;SCC、CYFRA21-1两者之间呈正相关,相关系数(r)为0.630。结论 SCC、CYFRA21-1在肺鳞癌中表达上调;SCC、CYFRA21-1与性别之间存在某种内在联系;SCC、CYFRA21-1与肺鳞癌的TNM分期呈正相关;SCC、CYFRA21-1阳性患者OS、PFS比阴性患者短;SCC、CYFRA21-1两者之间呈正相关,相关系数(r)为0.630。 相似文献
7.
8.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
9.
《Saudi Pharmaceutical Journal》2022,30(5):595-604
Anthrax is a zoonotic infection caused by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on the origin of the infection, serious health problems or mortality is possible. The virulence of B. anthracis is reliant on three pathogenic factors, which are secreted upon infection: protective antigen (PA), lethal factor (LF), and edema factor (EF). Systemic illness results from LF and EF entering cells through the formation of a complex with the heptameric form of PA, bound to the membrane of infected cells through its receptor. The currently available anthrax vaccines have multiple drawbacks, and recombinant PA is considered a promising second-generation vaccine candidate. However, the inherent chemical instability of PA through Asn deamidation at multiple sites prevents its use after long-term storage owing to loss of potency. Moreover, there is a distinct possibility of B. anthracis being used as a bioweapon; thus, the developed vaccine should remain efficacious and stable over the long-term. Second-generation anthrax vaccines with appropriate adjuvant formulations for enhanced immunogenicity and safety are desired. In this article, using protein engineering approaches, we have reviewed the stabilization of anthrax vaccine candidates that are currently licensed or under preclinical and clinical trials. We have also proposed a formulation to enhance recombinant PA vaccine potency via adjuvant formulation. 相似文献
10.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献